SERNYSEPharmaceutical PreparationsFiscal year ends December 31

Serina Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.65−0.07 (-4.07%)

Close on Oct 19, 2026

Market cap: $27.04M
P/E (TTM): –
Dividend yield: –

Serina Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	0.13	0.06	3.15	0.03	0.14	0.36	1.73	1.40	1.40
Cost of Revenue	–	–	0.04	0.01	0.02	0.03	0.24	0.36	0.17
Gross Profit	–	–	0.10	0.02	0.13	0.34	1.48	1.03	1.24
Research & Development	13	7.48	2.39	1.03	1.46	3.71	5.90	5.83	5.78
General & Administrative	11	9.62	3.89	5.97	6.71	6.72	8.14	5.65	3.87
Operating Expenses	24	17	6.28	7.00	8.16	10	14	-12	9.65
Operating Income	-24	-17	-3.13	-6.98	-7.93	-10	-13	-11	-6.66
Interest Expense	0.21	0.53	0.56	3.34	1.10	–	–	–	–
Other Non-Operating Income	4.83	5.84	8.40	-3.55	-0.65	-0.30	0.32	3.51	0.03
Asset Impairment Charges	0	0	0	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	0.35	3.22	–
Gain (Loss) on Sale of Assets	-0.09	0	0.07	–	–	–	–	–	–
Pretax Income	-19	-11	5.27	11	8.70	-11	-12	-7.73	–
Income Tax Expense	0.02	0	0	–	–	-0.15	0.15	–	–
Income from Continuing Operations	–	–	–	-10	-8.58	-10	–	–	–
Income from Discontinued Operations	–	–	–	–	-0.10	-0.73	–	–	–
Net Income incl. Noncontrolling Interests	-19	-11	5.27	-11	-8.69	-11	-12	-7.73	-6.64
Minority Interest in Earnings	-0.03	-0.07	0	-0.06	0.00	-0.11	-0.23	-0.23	-0.06
Net Income	-19	-11	5.27	-10	-8.68	-11	-12	-7.50	-6.58
Preferred Dividends	0.25	0	–	–	–	–	–	–	–
Net Income to Common	-19	-11	5.27	–	8.58	10	–	–	–
EPS (Basic)(per share)	-1.91	-1.51	2.36	-9.70	-0.23	-0.29	-0.33	-0.21	-0.21
EPS (Diluted)(per share)	-1.91	-1.51	0.73	-9.70	-0.23	-0.29	-0.33	-0.21	-0.21
Shares Outstanding (Basic, Weighted)(shares)	10	7.36	2.24	0.00	38	38	37	35	31
Shares Outstanding (Diluted, Weighted)(shares)	10	7.36	7.35	0.00	38	38	37	35	31
EBITDA	-24	-17	-3.04	–	–	-9.40	-12	-11	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -18478.5%
Net margin: -16288.5%
Return on equity, FY2025: -6351.7%

Financial strength

Current ratio: 6.65
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 612.0%

Valuation

P/E ratio: –
Price to sales: 207.96
Price to book: –
Dividend yield: –